Docket Number:28T-1060908
Inventor:An-Suei Yang, Hong-Sen Chen
IP Status:Know how
Abstract:
This invention provides a high-throughput screening of anti-PD-L1 antibodies with scFv (single chain variable fragment) phage-display methodology. Selected scFvs will be tested for their PD-1/PD-L1 blockade ability by in vitro binding and cell-based assays. Finally, candidate antibody leads will be converted into IgG format, and then test their in vivo animal efficacy using syngeneic mouse tumor model.
Fields of Application:
Development of monoclonal antibody for the treatments of gastric, ovarian, lung and renal carcinomas.
Advantages when compared to the existing technologies:
Recently, targeted therapies in combined with immunotherapy i.e. immune checkpoint blockade antibodies have showed promising results to improve clinical outcomes within a variety of cancer treatments. Thus, monoclonal antibody therapies against PD-L1 which is commonly over expressed on tumor cells or on non-transformed cells in the tumor microenvironment could lead to the activation of the cytotoxic T cells and improve the efficacy of cancer therapy.
Contact Person:
對本技術有興趣,請於本處網頁廠商選項下(廠商需求與諮詢)網頁填寫資料,承辦人將跟您聯絡。
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Apply for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office, and the undertaker will contact you
